theHeart.org - Thrombosis Risk

US updates advice on perioperative beta-blocker use in noncardiac surgery

Tue, 03 Nov 2009 14:30:32 EST

A US update on the perioperative use of beta blockers for noncardiac surgery is, says the lead author, "similar" to recent European guidance on this issue.

Combined home/GP hypertension control program successful in Pakistan

Mon, 02 Nov 2009 17:00:00 EST

A synergistic approach of educating general practitioners about hypertension control together with a program to send lay workers into people's homes to educate them about the management of high blood pressure has proven successful in low- to middle-income households in Pakistan.

Imaging study shows plaque regression with niacin vs placebo

Fri, 30 Oct 2009 16:00:00 EDT

Just weeks before ARBITER-HALTS�6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumes—the more commonly seen end point with MRI.

Distribution of body fat important in VTE

Mon, 26 Oct 2009 16:00:00 EDT

The distribution of body fat, as well as the amount, is important when it comes to the risk of venous thromboembolism, Danish researchers have discovered.

Cardiovascular disease increases risk of hip fracture

Tue, 20 Oct 2009 16:00:00 EDT

Swedish researchers have confirmed a link between stroke and subsequent hip fracture in older people and identified for the first time that a diagnosis of heart failure also increases the risk for this fracture. They also identify a large genetic component to this association, via their use of a twin registry.

ACE inhibitors of benefit in ischemic heart disease patients with preserved LV function

Mon, 19 Oct 2009 17:00:00 EDT

Patients with ischemic heart disease and preserved LV function on standard therapy will gain additional benefit from taking ACE inhibitors, a new review concludes. The same cannot be said for ARBs, a drug class for which the evidence is much weaker, but these are a good substitute in those who cannot tolerate ACE inhibitors, the authors say.

TYCOON: One year of dual-antiplatelet therapy with DES isn't enough

Mon, 19 Oct 2009 12:45:34 EDT

New results from an Italian registry reopen the question of how long drug-eluting stent recipients should stay on a dual antiplatelet regimen to prevent late thrombosis.

Transfusion in acute HF: No extra mortality risk

Mon, 19 Oct 2009 11:00:10 EDT

Blood transfusions for anemia in acute decompensated heart failure don't exacerbate outcomes, as may happen in some ACS cases, suggests a one-year experience of hospitals in Israel. On the contrary�.�.�.�

Zero CAC score not 100% reassuring in those presenting to ER with chest pain

Fri, 16 Oct 2009 12:45:08 EDT

In those presenting to the ER with chest pain, a prior zero calcium score cannot completely rule out a coronary obstruction, a new analysis of the MESA study has shown. This is likely due to the presence of soft plaques not detected by calcium screening, the researchers say.

Racial background woefully underreported in CV trials

Thu, 15 Oct 2009 13:15:10 EDT

Two-thirds of the 156 trials considered by the AHA in preparing a recent guideline failed to even record the ethnic backgrounds of participants, a new study has found. The researchers call for the reporting of race/ethnicity to be mandatory in all clinical trials, and they suggest medical journals should enforce this policy.

Scripps starts routine genetic testing for clopidogrel responsiveness

Wed, 14 Oct 2009 11:00:05 EDT

Scripps Health has announced that it is now offering patients undergoing elective stenting a test for the gene variants associated with an inability to convert clopidogrel to its active metabolite so that antiplatelet therapy can be individualized.

Diuretics effective as second-line therapy for hypertension

Tue, 13 Oct 2009 12:00:48 EDT

Diuretics, especially hydrochlorothiazide, are as effective when given as second-line therapy for high blood pressure as they are when used as initial treatment, according to the first review to look at this issue.

Hopes build for natriuretic-peptide risk stratification before noncardiac surgery

Tue, 13 Oct 2009 10:00:10 EDT

Could a preoperative blood assay take the place of imaging studies or other more costly assessments of cardiovascular risk? A meta-analysis suggests yes. A massive randomized trial is looking into it now.

Glucocorticoids seen to double risk of atrial arrhythmias

Mon, 12 Oct 2009 16:00:00 EDT

In a case-control study from Denmark, the risk of atrial fibrillation or flutter was significantly increased with current but not previous use of glucocorticoids for chronic obstructive pulmonary disease, rheumatoid arthritis, and other conditions.

Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim

Fri, 09 Oct 2009 16:45:25 EDT

Diabetologists are trying to tease out the best message to convey when it comes to target HbA_1c levels for primary-care physicians and other nonspecialists who might be treating patients with type 2 diabetes.

Coronary thrombosis�the culprit is not just plaque rupture

Thu, 08 Oct 2009 17:45:48 EDT

Clots derived from a different source—erosions of the arterial wall—may be an important cause of MI and sudden death, particularly in younger women, who may need a different approach to treatment, new research suggests.

New review confirms homocysteine lowering does not prevent CVD events

Thu, 08 Oct 2009 15:30:45 EDT

The latest review to look at the effects of homocysteine lowering with vitamin-B supplementation has come to much the same conclusions as most other studies and analyses in this field.

Lupus anticoagulant a major risk factor for stroke and MI in young women

Wed, 07 Oct 2009 10:00:40 EDT

Results of the RATIO study suggest lupus anticoagulant, but not anticardiolipin or antiprothrombin antibodies, is associated with increased stroke risk and to a lesser extent MI.

China death toll due to hypertension worse than predicted

Tue, 06 Oct 2009 14:15:24 EDT

The first prospective study using real data to inform the number of people suffering from and dying due to high blood pressure in China finds the problem is much worse than previously thought. A number of initiatives are planned to try to tackle this crisis.

20�000-patient DAPT clinical trial starts enrolling with eight industry sponsors on board

Mon, 05 Oct 2009 16:45:09 EDT

The trial, rumored to cost more than $100 million, is a first for collaboration: eight drug and device companies are backing the trial, along with the FDA. The study is powered to detect a difference in stent thrombosis and major adverse events between patients taking 12 or 30 months of aspirin plus clopidogrel or prasugrel.

Hypoglycemia associated with increased risk of MI among US veterans with diabetes

Mon, 05 Oct 2009 13:45:19 EDT

Close attention should be paid to diabetes patients who experience an episode of hypoglycemia, because a new case-control study suggests a 65% increased risk of MI in the immediate two-week aftermath of such an event. Doctors should tailor diabetes therapies to minimize the risk of hypoglycemia occurring, say the researchers.

New "principles" on authorship and COI from PhRMA get mixed response

Fri, 02 Oct 2009 12:00:10 EDT

The "Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results" echo recent standards set by medical journal editors, but some observers say the document, which has no penalty component, lacks real teeth.

HORIZONS analysis: 600-mg clopidogrel load preferable in primary PCI

Thu, 01 Oct 2009 16:00:46 EDT

The higher dose was associated with a reduced rate of ischemic events without an increase in bleeding in patients with STEMI undergoing primary PCI.

Early statin therapy in ACS: What's the level of evidence?

Mon, 28 Sep 2009 17:00:00 EDT

The use of high-dose statin therapy early in the course of acute coronary syndrome currently has the highest possible (class IA) recommendation in US guidelines, but a group of experts argues that this is inaccurate based on current evidence. However, they stress, they are not saying statins should not be used in this indication.

CHARISMA Genomics Substudy links loss-of-function allele and bleeding

Mon, 28 Sep 2009 14:15:11 EDT

Patients who are homozygous for the CYP2C19*2 allele are at increased risk of ischemia but less likely to bleed. Routine genotyping for the variant still isn't recommended.

Skin lesions from heparin more common than thought

Mon, 28 Sep 2009 12:00:00 EDT

A new prospective study has found the incidence of heparin-induced skin lesions to be around 7.5%. Women, the obese, and those on heparin therapy for longest are most at risk.

Reduced bleeding and comparable stent thrombosis with DES and bare-metal stents: HORIZONS-AMI at two years

Fri, 25 Sep 2009 17:55:17 EDT

Two-year data showed significant reductions in bleeding and cardiac mortality in patients treated with bivalirudin when compared with those treated with heparin plus a GP IIb/IIIa inhibitor. In the stent arm of the trial, researchers showed that stent thrombosis rates were equivalent between DES and bare-metal stents, although both rates were high, at 4.1%.

PLATO-Invasive: Impressive ticagrelor results mirror overall trial findings

Fri, 25 Sep 2009 17:30:21 EDT

The prespecified subset analysis helps clarify the performance of the drug in patients managed invasively, including adding new insights into its benefits over both the 300-mg and 600-mg loading doses of clopidogrel.

COMPARE: "Real-world" randomized trial favors Xience V over Taxus Libert�

Fri, 25 Sep 2009 08:30:19 EDT

COMPARE is the second of two large randomized controlled trials comparing a Taxus stent with Xience V to show a clear benefit of the newer stent.

COGENT: No CV events but significant GI benefits of PPI omeprazole

Thu, 24 Sep 2009 16:30:07 EDT

The randomized controlled trial results should put a stop to alarmist headlines about PPIs blunting efficacy of antiplatelet drugs, experts say. By withholding PPIs, physicians are doing more harm than good, the results suggest.

SIRTAX LATE: No differences in MACE for first-generation stents at five years

Thu, 24 Sep 2009 08:30:17 EDT

After one year, Cypher had lower rates of death, MI, or repeat PCIs than Taxus in the SIRTAX trial. But four years later, investigators say all differences between the two have disappeared, in part due to more late "catch-up" with the Cypher.

SPIRIT IV: Xience V trumps Taxus for clinically driven end points, although diabetic questions linger

Wed, 23 Sep 2009 16:15:24 EDT

UPDATED // Rates of target lesion failure were significantly lower for the everolimus-eluting Xience V stent for the trial as a whole. In diabetic patients only, however, no differences were seen between the two stents.

Enoxaparin cheaper than UFH in STEMI patients undergoing thrombolysis?

Tue, 22 Sep 2009 17:15:18 EDT

A new analysis of the EXTRACT-TIMI 25 trial concludes that enoxaparin is slightly cheaper in the long term than unfractionated heparin for STEMI patients undergoing thrombolysis. But there are questions as to why 30-day data and not one-year results were used to model long-term cost-effectiveness.

Three-year SPIRIT III results show enduring edge for Xience V over Taxus

Tue, 22 Sep 2009 11:45:00 EDT

Three-year target vessel failure remained statistically lower for the everolimus-eluting Xience V stent (which is also marketed as the Promus) than for the paclitaxel-eluting Taxus stent.

ENDEAVOR IV: Revascularization rates similar for Endeavor and Taxus at three years, with Endeavor "pulling ahead" for safety

Tue, 22 Sep 2009 09:45:47 EDT

Rates of cardiac death and MI actually statistically favor the Endeavor stent at three years, new data show. Stent thrombosis occurred just once after one year for Endeavor, as compared with 11 cases after the one-year mark in the Taxus-treated patients.

Flu vaccine may protect against MI

Mon, 21 Sep 2009 18:30:00 EDT

A protective effect was seen in patients with established cardiovascular disease. Whether vaccination is protective in people with no vascular disease is less clear, a new review suggests.

Coumarin derivatives affect clopidogrel action

Thu, 17 Sep 2009 12:00:47 EDT

Another interaction that may affect the response to clopidogrel has been reported, this time with the coumarin derivative phenprocoumon, an anticoagulant commonly used in Europe.

Cutting salt intake in US could save $50 billion a year

Thu, 17 Sep 2009 11:00:49 EDT

A new economic analysis concludes that regulations to reduce sodium content in processed foods and/or voluntary reductions in salt by companies could save up to $50 billion a year in healthcare costs in the US.

Physician, teach thyself: IMPROVE-HF initiative boosts use of evidence-based outpatient care

Wed, 16 Sep 2009 17:45:55 EDT

The two-year prospective registry-based study of a performance-improvement initiative's effectiveness saw significant jumps, >70% in some cases, in the appropriate use of six out of seven measured evidence-based treatments for patients with chronic heart failure.

New ASCOT analysis: Beta blockers not beneficial in hypertensives with tachycardia

Tue, 15 Sep 2009 14:15:57 EDT

Pulse rate should not be the determinant of which drugs are used in hypertension, conclude the authors of a new subgroup analysis of the ASCOT trial.

Conflicts of interest affect best practices in both industry-funded and non-industry-funded trials

Tue, 15 Sep 2009 12:00:19 EDT

Clinicians and researchers need to be more aware before signing on to studies about what potential conflicts might arise with the sponsor and set the ground rules for such areas as access to data, manuscript preparation, and right to publish.

Who should get CRT? Resynchronization benefits seen in heart failure with LVEF >35%

Mon, 14 Sep 2009 17:15:00 EDT

Heart-failure patients with ejection fractions >35% aren't necessarily excluded from the clinical and reverse-remodeling benefits of cardiac resynchronization therapy, suggests yet another study questioning the limits of CRT's current eligibility criteria.

ICDs in women with heart failure? Won't work, suggests meta-analysis

Mon, 14 Sep 2009 16:00:00 EDT

Implantable defibrillators don't cut all-cause mortality in women with systolic heart failure, proclaim five major clinical trials speaking in unison. An editorial writer cries "foul" on the frequent assumption in clinical practice that outcomes data from randomized trials conducted primarily in men should also apply to women.

Sponsorship of med-school textbooks in Denmark exposes vulnerable minds to commercial bias

Mon, 14 Sep 2009 11:45:00 EDT

Results of a new survey showed that a surprising 15% of textbooks had one or more drug or device sponsors and, in two cases, those sponsors had tried to influence the content of the textbooks.

Spin not uncommon in negative RCTs, study shows

Mon, 14 Sep 2009 11:30:00 EDT

French researchers who systematically quantified the prevalence of spin across 72 negative randomized controlled trials say half of the studies put a positive spin on the negative findings in the conclusion sections of the papers.

Homocysteine lowering cuts mortality in early-onset CAD patients

Fri, 11 Sep 2009 12:00:04 EDT

A new Israeli study finds that treatment with folic acid/B vitamins long term did significantly reduce mortality, but only in those with elevated homocysteine levels at baseline.

Ghost authorship on the wane, but guest authorship still common

Fri, 11 Sep 2009 11:00:38 EDT

UPDATED // Compared with a 1996 survey by JAMA editors, a 2008 survey indicates that the practice of having ghost writers pen papers, then not appear as authors, is down to 8%, from 12% in 1996. The practice of inviting a prominent name to appear in the list of authors, without requiring that person to contribute to the research, has held steady at roughly 20%.

Dronedarone in atrial fib trades efficacy for safety in meta-analysis

Fri, 11 Sep 2009 10:15:53 EDT

The finding, based on eight randomized trials, supports the view that dronedarone is less effective than amiodarone at preventing the arrhythmia's recurrence but doesn't have the older drug's serious toxicities, as suggested by the DIONYSOS trial.

MIST correction published; no new information on disputed echo review for PFO/migraine trial

Wed, 09 Sep 2009 14:30:44 EDT

UPDATED // The correction in Circulation runs over 700 words long, with a four-page data supplement, but includes no details on residual-shunt data allegedly obtained with an "off-protocol" review of the echocardiographic results.

UK NICE recommends limited role for prasugrel

Tue, 08 Sep 2009 14:00:15 EDT

The UK agency that governs reimbursement advises that prasugrel can be used in those ACS patients undergoing PCI who have STEMI, who are diabetic, or who have had a stent thrombosis on clopidogrel.

European CRT Survey: Indications in real life often ahead of guidelines

Fri, 04 Sep 2009 17:30:50 EDT

In Europe, cardiac resynchronization therapy in clinical practice is applied to many patients for whom there is no supporting clinical-trial evidence, including those with atrial fib and patients older than 75.